NCT03510104已完成1 期
A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Meryx, Inc.
- 入组人数
- 42
- 试验地点
- 2
- 主要终点
- Percentage of subjects with Dose Limiting Toxicities (DLTs)
研究概览
简要总结
This first-in-human open-label, dose escalation study is designed to evaluate the safety, tolerability, and PK of MRX-2843 in subjects with relapsed/refractory advanced and/or metastatic solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female at least 18 years of age.
- •Histologically or cytologically confirmed, measurable (defined as those that could be accurately measured in a least 1 dimension with a longest diameter ≥20 mm using conventional techniques or ≥10 mm with spiral computed tomography scan) or evaluable solid malignancy (with the exception of primary central nervous system [CNS] tumors) per RECIST 1.
- •Scans performed within 1 month of starting study drug will be accepted.
- •Received at least one systemic therapy for advanced disease, with no further approved treatment options that provide proven clinical benefit.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Females of childbearing potential who are sexually active with a nonsterilized male partner agree to use 2 methods of effective contraception from screening, and agree to continue using such precautions for 90 days after the final dose of study drug; cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control.
- •Nonsterilized males who are sexually active with a female of childbearing potential must agree to use an acceptable method of effective contraception from Day 1 and for 90 days after the final dose of study drug.
- •Female subjects of childbearing potential must be nonpregnant, nonlactating, and have a negative pregnancy test result at Screening and Day 1 of Cycles 1-
- •Able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the Investigator, to comply with all the requirements of the study.
- •Able to swallow oral medication.
- •Subject has the following laboratory values at Screening:
- •Absolute neutrophil count ≥1500/mm3
- •Platelet count ≥100,000/mm3
- •Hemoglobin ≥9.0 g/dL (must be >2 weeks post-red blood cell transfusion)
- •Bilirubin ≤1.5x the upper limit of normal (ULN). For subjects with documented Gilbert's disease, bilirubin ≤3.0 mg/dL. For subjects with documented liver metastases, bilirubin ≤ 2.5x ULN.
- •Serum creatinine ≤1.5x the ULN or creatinine clearance (CrCl) ≥50 mL/min.
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3x the ULN (≤5x the ULN for subjects with liver metastases)
排除标准
- •Subject has an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically significant and would preclude study participation.
- •Subject has QT interval corrected (QTc) >480 ms (both males and females) at Screening (repeat values may be obtained during the period between Screening and admission to the study site).
- •Subject has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study drug, or any other condition that may place the subject at risk for such interference (for example, short bowel syndrome or inflammatory bowel disease).
- •Subject has a history of Type 1 Diabetes (T1D) or is considered at high risk for T1D, where high risk is defined as
- •Subject has 1 first-degree relative (FDR; defined as parents, offspring or siblings) with T1D AND A1C value > 6.5% or
- •Subject has 2+FDR with T1D
- •Subject has uncontrolled hypertension, defined as a blood pressure reading >160/100 mmHg, despite maximum antihypertensive therapy.
- •Subject has received:
- •Radionuclide treatment within 6 weeks of the first dose of study drug in this study
- •Local palliative radiation therapy (XRT) (small port) ≤2 weeks before first dose of study drug
- •Treatment with therapeutic doses of metaiodobenzylguanidine (MIBG) ≤6 weeks before first dose of study drug
- •Prior total body irradiation, total craniospinal XRT, or ≥50% radiation of pelvis within 6 months of receiving first dose of study drug
- •Treatment with a monoclonal antibody within 28 days or 5 half-lives, whichever is shorter, from treatment with first dose of study drug
- •Therapy with a growth factor within 7 days of starting study drug
- •Chemotherapy within 3 weeks of starting study drug (6 weeks if prior nitrosourea)
- •Subjects receiving systemic (oral or parenteral) corticosteroid therapy within 7 days of first dose of study drug or a requirement for chronic systemic immunosuppressive therapy for any reason. Topical or inhaled steroids are allowed.
- •Subject has not fully recovered to baseline or National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) ≤ Grade 1 from toxicity due to all prior therapies, except alopecia and other non-clinically significant AEs.
- •Subject has any history of human immunodeficiency virus (HIV) or immunodeficiency at Screening.
- •Subject has a diagnosis of chronic active hepatitis B or C.
- •Subject has uncontrolled intercurrent illness including, but not limited to ongoing or active bacterial, fungal, or viral infection requiring intravenous therapy (not prophylaxis) at the time of study enrollment, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Subject has a history of a major adverse cardiac event, including cerebrovascular accident or myocardial infarction within the prior 6 months, or uncontrolled congestive heart failure (New York Heart Association class 3 or 4) at Screening.
- •Subject has active, suspected, or previously documented autoimmune disease, defined as requiring systemic treatment.
- •Subject has known or suspected history of retinitis pigmentosa or known or suspected familial history of retinitis pigmentosa.
- •Subject has prothrombin time/International Normalized Ratio or partial thromboplastin time test results at screening ≥1.5 x ULN.
- •Subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin-related agents, thrombin or FXa inhibitors, or antiplatelet agents (eg, clopidogrel). Low-dose aspirin (≤81 mg/day), low-dose warfarin (≤1 mg/day), and prophylactic low molecular weight heparin are permitted.
- •Subject had surgery (excluding line insertions) within 1 month of the first dose of study drug or has lingering wound complications.
- •Subject is unable or unwilling to abide by the study protocol or cooperate fully with the Investigator or designee.
研究组 & 干预措施
MRX-2843
Experimental
MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD
干预措施: MRX-2843 (Drug)
结局指标
主要结局
Percentage of subjects with Dose Limiting Toxicities (DLTs)
时间窗: Baseline to the end of Cycle 1 (up to 28 days)
Percentage of subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5
时间窗: Baseline up to 14 days after last dose of study treatment (up to approximately 12 months)
次要结局
- CL/F: apparent total body clearance(Day 1 and Day 16 of Cycle 1)
- Determine Maximum Tolerated Dose (MTD) in mg of MRX-2843(Baseline to end of Cycle 1 (up to 28 days))
- AUC0-t: area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (t)(Day 1 and Day 16 of Cycle 1)
- AUC0-inf: area under the concentration-time curve from time 0 to infinity(Day 1 and Day 16 of Cycle 1)
- AUC0-τ: area under the concentration-time curve from time 0 to tau, where tau is the dosing interval(Day 1 and Day 16 of Cycle 1)
- Cmax: maximum observed plasma concentration(Day 1 and Day 16 of Cycle 1)
- Tmax: time to reach maximum observed plasma concentration(Day 1 and Day 16 of Cycle 1)
- λz: terminal phase elimination rate constant(Day 1 and Day 16 of Cycle 1)
- t1/2: apparent terminal elimination half-life(Day 1 and Day 16 of Cycle 1)
- Vz/F: apparent volume of distribution of the terminal phase(Day 1 and Day 16 of Cycle 1)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Study of LM-061 in Subjects in Advanced TumorsAdvanced TumoursNCT04737122LaNova Medicines Limited18
终止
1 期
Study of LM-102 in Subjects in Advanced TumorsAdvanced Solid TumorsNCT04735796LaNova Medicines Limited9
已完成
1 期
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid TumorsTumorsHematologic MalignanciesNCT01375842Genentech, Inc.661
招募中
1 期
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis BHEPATITIS B CHRONICNCT06680232Precision BioSciences, Inc.45
已完成
1 期
A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid TumorsAdvanced Solid TumorNCT04116710Heat Biologics15